CONDUCT RACEHORSE TESTING IN ACCORDANCE WITH THE RACING MEDICATION TESTING CONSORTIUM (RMTC) AND THE ISO17025 INTERNATIONAL STANDARD 1. Analyses for alleged performance-enhancing drugs in submitted contraband samples (e.g., vials, loaded syringes, tubes of paste) by UC DAVIS methods including, but not limited to, LC-MS/MS, GC/MS, LC-HRAMS, or ELISA as requested by TXRC. a) Specimen sample testing and split specimen sample testing, upon licensee request, made through TXRC for the purpose of confirming the presence of prohibited substances and controlled therapeutic medications on equine urine specimen samples as follows: b) Instrumental analysis (e.g., LC-MS/MS, GC/MS, LC-HRAMS, ICP-MS and IC-MS) on each equine urine specimen sample. c) Specific gravity determination on each equine urine specimen sample with an accompanying serum furosemide concentration in excess of 100 ng/ml. d) Each specimen sample with the presence of a therapeutic medication, at levels as published by TXRC, that exceed the maximum permissible concentration level shall be reported by UC DAVIS to TXRC as a positive result with the quantitative level and MU of the therapeutic medication. e) Upon request by TXRC, specimen samples shall be tested by UC DAVIS for arsenic. Testing for arsenic shall be performed using ICP/MS, and the regulatory threshold maximum permissible...
